Cognitive impairment (CI) frequently occurs in patients with systemic lupus erythematosus (SLE) and may result from neuroinflammation processes and neurovascular changes in the brain. The cerebral hemodynamics underlying SLE with CI (SLE-CI) remain unclear. 97 patients with SLE and 51 heathy controls (HCs) matched for age and gender underwent MRI. The CI status of patients was measured using the MoCA, and we classify those with a score of 28 or above as the SLE cognitive normal group (SLE-NC). 3D T1-weighted, ASL and resting-state functional (rs-fMRI) sequences were obtained. Seed-based functional connectivity (FC) was calculated using the cerebral blood flow (CBF) results. Compared with SLE-NC, patients with SLE-CI had higher CBF in the left hippocampus, thalamus, and cerebellum crus II and lower CBF in the left frontal lobe. Secondary analyses revealed that compared with patients with SLE-NC, patients with SLE-CI had increased FC of the left insula gyrus when the left cerebellum crus II was set as the seed region and decreased FC in the homolateral para-hippocampus when the left hippocampus was set as the seed region. These structural, functional, and network changes may serve as potential biomarkers for cognitive impairment in SLE-CI patients.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-025-85648-1DOI Listing

Publication Analysis

Top Keywords

cognitive impairment
12
systemic lupus
8
lupus erythematosus
8
sle-nc patients
8
patients sle-ci
8
cbf left
8
left hippocampus
8
cerebellum crus
8
set seed
8
seed region
8

Similar Publications

Background: The presence of multiple comorbid pathologic features in late-onset dementia has been well documented across cohort studies that incorporate autopsy evaluation. It is likely that such mixed pathology potentially confounds the results of interventional trials that are designed to target a solitary pathophysiologic mechanism in Alzheimer's disease and related dementias (ADRD).

Method: The UK ADRC autopsy database was screened for participants who had previously engaged in therapeutic interventional trials for Alzheimer's disease, vascular cognitive impairment, dementia, and/or ADRD prevention trials from 2005 to the present.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Clario, Philadelphia, PA, USA.

Background: Clinical outcome assessments (COAs) are an important part of clinical trials to measure what is meaningful to patients and caregivers. This study aimed to examine trends in Alzheimer's Disease (AD) COAs used in clinical trials, given the FDA's recent emphasis on patient-focused drug development and early AD.

Method: ClinicalTrials.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.

Background: The DL-3-n-butylphthalide (NBP), a multi-target neuroprotective drug, improving cognitive impairment in patient with vascular cognitive impairment has been confirmed. The efficacy of NBP in patients with cognitive impairment due to Alzheimer's disease (AD) remains unknown. This study aimed to evaluate the efficacy and safety of NBP in patients with mild cognitive impairment (MCI) due to AD though a clinical randomized controlled trail.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

AIMST University, Bedong, Kedah, Malaysia.

Background: Senile dementia (SD) is a deteriorative organic brain disorder and it comprises Alzheimer's disease (AD) as a major variant. SD is shown impairment of mental capacities whereas AD is degeneration of neurons. According to World Health Organization (WHO) report; more than 55 million peoples have dementia and it is raising 10 million new cases every year.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

EQT Life Sciences Partners, Amsterdam, 1071 DV Amsterdam, Netherlands.

Background: Alzheimer's disease (AD) trials report a high screening failure rate (potentially eligible trial candidates who do not meet inclusion/exclusion criteria during screening) due to multiple factors including stringent eligibility criteria. Here, we report the main reasons for screening failure in the 12-week screening phase of the ongoing evoke (NCT04777396) and evoke+ (NCT04777409) trials of semaglutide in early AD.

Method: Key inclusion criteria were age 55-85 years; mild cognitive impairment due to AD (Clinical Dementia Rating [CDR] global score of 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!